Company

Pacific Edge Ltd

Headquarters: Dunedin, New Zealand

NZX: PEB +7.58%

Detailed Description

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product designed to identify high grade or late stage bladder cancer and provide increased clinical resolution; Cxbladder Triage, a product that analyses the gene expression of urine-based biomarkers alongside information on known bladder cancer risk factors like age, gender, and smoking history to rule out patients with a low risk of having the disease; Cxbladder Detect that can be used as an adjunct to cystoscopy or as a substitute for other urine-based tests or imaging procedures; and Cxbladder Monitor, which is a non-invasive and easy-to-use test to rule out the return of bladder cancer. In addition, the company is developing Cxcolorectal (prognosis Gen II), a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Pacific Edge Ltd has the following listings and related stock indices.


Stock: NZX: PEB wb_incandescent

Stock: ASX: PEB wb_incandescent

Stock: OTC: PFGTF wb_incandescent

Details

Headquarters:

Centre for Innovation

87 St David Street PO Box 56

Dunedin, 9016

New Zealand

Phone: 64 3 479 5800

Fax: 64 3 479 5801